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Previewsthe ATRX/Daxx pathway in ALT. It has
been shown that tankyrase loss in non-
ALT cells causes persistent telomere
cohesions and cell arrest in anaphase of
mitosis (Dynek and Smith, 2004). How
do ALT cells with delayed resolution of
sister telomere cohesion manage to
circumvent this blockade in the cell
cycle? Do other shelterin members, such
as the tankyrase-binding partner TRF1,
play any role in this aspect of the ALT
pathway?
In ALT, the telomeres must first find
each other to recombine, and they have
a choice whether to shop locally or to
sample further afield. What influences
this choice and what the consequences
of this decision are will help us tobetter understand the role of telomeric
recombination in ALT and determine
how telomerase-negative cancer cells
acquire immortal growth properties.REFERENCES
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Current BRAF inhibitors block signaling from monomeric BRAFV600E, but not from oncogenic RAS, which
requires RAF dimerization. In this issue of Cancer Cell, Yao and colleagues investigate why current drugs
are ineffective against RAF dimers, while Peng and colleagues describe a pan-RAF inhibitor targeting both
monomeric and dimeric RAF.Mutations in RAS family members and
BRAF are important cancer drivers in
>30% of human malignancies, and up-
regulation of canonical RAS/RAF/MEK/
ERK signaling is observed in the majority
of tumors. The extensive nature of onco-
genic signaling through this pathway
has made the identification of RAS
and RAF inhibitors a top priority of
drug discovery programs for over two
decades. Although agents that block
RAS activity remain elusive, the devel-
opment of BRAF kinase inhibitors pro-
gressed steadily, with vemurafenib be-
ing the first to gain Food and Drug
Administration (FDA) approval in 2011
for the treatment of malignant melanomadriven by BRAFV600E, the most prevalent
BRAF mutation. Vemurafenib and other
first generation BRAF inhibitors exhibit
good efficacy against BRAFV600E and
have been touted as another success
story for targeted therapeutics; howev-
er, several early observations tempered
enthusiasm.
In particular, these drugs had little ac-
tivity against tumors possessing RASmu-
tations, even though the RAF kinases are
essential downstream effectors of RAS
(Fedorenko et al., 2011). In cell-based
assays, researchers further found that,
while these inhibitors were effective at
shutting down ERK signaling mediated
by BRAFV600E, they paradoxically upregu-lated ERK activity in the presence of
oncogenic RAS (Gibney et al., 2013).
Moreover, a subset of melanoma patients
treated with these drugs developed
secondary malignancies, many of which
arise from cells harboring pre-existing
RAS mutations. Finally, the effectiveness
of current BRAF inhibitors in treating
BRAFV600E-driven melanoma is short-
lived, with drug resistance invariably
developing, often as a result of ERK
cascade reactivation (Bucheit and Da-
vies, 2014).
The apparent limitations to the useful-
ness of these drugs, however, were not
without a silver lining in that they stimu-
lated a flurry of investigation that hasptember 14, 2015 ª2015 Elsevier Inc. 279
Figure 1. Next-Generation RAF Inhibitors
(Left) Oncogenic BRAF mutants evade normal ERK-mediate feedback inhibition and gain RAS-indepen-
dence by functioning as either activated monomers or constitutive homodimers. Current BRAF drugs
block signaling from activated monomers, but not dimeric RAF, due to negative cooperativity in protomer
binding. (Right) Next-generation pan-RAF inhibitors target RAF monomers and dimers.
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Previewssignificantly advanced our understanding
of the RAF kinases. The studies by Yao
et al. (2015) and Peng et al., (2015) in
this issue ofCancer Cell are no exception,
providing explanations for the limited
effectiveness of current BRAF inhibitors,
elucidating mechanisms for how different
BRAF mutants promote tumorigenesis,
and describing new RAF inhibitors with
broader activity.
At the time that the first generation
BRAF therapies entered the clinic, signal
transmission fromRAS to RAFwas known
to be complex, with gaps still remaining in
our understanding of RAF kinase activa-
tion. Through experiments characterizing
the paradoxical upregulation of ERK
cascade signaling induced by these drugs
in RAS mutant cells, the issue of RAF
dimerization came to the forefront, with
inhibitor treatment appearing to promote
or stablize RAF dimer formation (Lavoie
et al., 2013). Through subsequent mutant
analysis and structural studies, it is now
know that RAF dimerization is an obliga-
tory step in RAS-mediated RAF activation
(Freeman et al., 2013). Like most kinases,
to become an active enzyme the RAF cat-
alytic domain must assume a closed
conformation with the conserved DFG
motif swinging in to align the regulatory
spine. Under normal signaling conditions,
formation of this active conformation oc-
curs through an allosteric transactivation
mechanism that is mediated by RAF280 Cancer Cell 28, September 14, 2015 ª20dimerization and requires RAS binding to
promote dimer formation (Hu et al.,
2013). This allosteric mechanism has
been best characterized for Ras-induced
BRAF/CRAF heterodimers where BRAF
activates CRAF; however, ARAF/BRAF
heterodimers as well as BRAF/BRAF and
CRAF/CRAF homodimers have also
been observed.
Perhaps not surprising, the signaling
activity of BRAFV600E bypasses this Ras-
mediated dimerization step, and structure
modeling studies would suggest that the
valine to aspartic acid substitution itself
allows this mutant to adopt the active ki-
nase conformation in the absence of the
allosteric mechanism, thus functioning
as an activated monomer (Hu et al.,
2013). Although V600E is the most preva-
lent BRAF mutation, many other BRAF
mutations have been detected in human
cancers, the majority of which have
increased kinase activity. In this issue of
Cancer Cell, Yao et al. (2015) investigate
the mechanisms by which various acti-
vated BRAF mutants promote tumorigen-
esis. Utilizing elegant cell based systems
and mutational analysis, they find that a
common property of these activated pro-
teins is their ability to signal in a RAS-inde-
pendent manner, thus evading normal
mechanisms of pathway attenuation
(Figure 1). Under physiological conditions,
signaling through the RAS/RAF/MEK/
ERK is regulated by ERK-mediated feed-15 Elsevier Inc.back inhibition (Lito et al., 2012). Through
direct phosphorylation events and by
increasing the expression of pathway in-
hibitors, ERK acts at multiple points
to limit RAS-GTP levels, which in turn
modulates the amplitude and duration of
pathway signaling. Like BRAFV600E, Yao
et al. (2015) found that all oncogenic sub-
stitutions in V600 provided RAS-indepen-
dence by allowing BRAF to function as an
activated monomer. In contrast, other
activated BRAF mutants formed constitu-
tive homodimers that did not require RAS
activity for dimerization. Moreover, they
found that the mechanism by which the
mutants gained their RAS independence
determined their sensitivity to current
BRAF drugs. More specifically, activated
monomers were inhibited by these drugs,
but homodimeric mutants were not. The
BRAF drugs currently in the clinic are
classified as type I inhibitors that bind to
the active ‘‘DGF-in’’ kinase conformation,
and further investigation by Yao et al.
(2015) revealed that binding of these
drugs to one protomer in the dimer signif-
icantly reduced the affinity for binding to
the second protomer, demonstrating
negative cooperativity (Figure 1). The au-
thors go on to identify a RAF inhibitor,
BGB659, with equivalent efficacy against
both the monomeric and homodimeric
BRAF mutants; however, the IC50 for
monomeric BRAF was found to be higher
than current BRAF drugs, and BGB659
was ineffective against WT RAF dimers
in cells expressing RAS mutations.
Also in this issue, Peng et al. (2015)
characterize a new pan-RAF inhibitor
LY3009120 that is capable of inhibiting
monomeric BRAFV600E as well as WT
and mutant RAF dimers. LY3009120
binds all RAF family members with similar
affinities and inhibits their kinase activity
with half-maximal inhibitory concentra-
tions (IC50s) in the low nanomolar range.
Although LY3009120 strongly induced
RAF dimerization in the presence of
oncogenic RAS, minimal activation of
MEK and ERK was observed, indicating
that the activity of the induced dimers
was effectively blocked. In cell culture as-
says and xenograph studies, LY3009120
inhibited the growth of tumor cells ex-
pressing BRAF or RAS mutations. Peng
et al. (2015) propose that the high affinity
for CRAF and the way in which
LY3009120 binds the RAF kinase domain
likely explains its effectiveness against
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Previewsboth BRAF and RAS mutant cells. Struc-
tural analysis revealed that LY3009120
could occupy both protomers in a RAF
dimer and that it was selective for the
inactive, ‘‘DFG-out’’ kinase conforma-
tion, designating it a type II inhibitor.
The accessibility of the ATP binding
pocket allowed by this conformation
may explain how this and other type II in-
hibitors, including BGB659 described
above and two recently reported RAF in-
hibitors (Girotti et al., 2015), can bind
both protomers with similar affinity.
It is clear that the path forward for
more effective RAF therapies will require
drugs that can inhibit both monmeric
and dimeric RAF (Figure 1). Moreover, in-
hibitors that target all RAF members
may expand their use to tumors with up-
stream pathway activation. Determining
the efficacy of these drugs in patients
as well as the potential mechanisms ofdrug resistance will be critical. For the
first generation BRAF inhibitors, drug
resistance has often involved RAF dimer-
ization. However, now, with compounds
that can inhibit RAF dimers, what mech-
anisms will tumor cells use to evade
death? Will mutations that disable
inhibitor binding, such as gatekeeper
mutations, now be observed? Only time
will tell.REFERENCES
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NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use inmul-
tiplemyeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bonemarrow,
are well tolerated, and produce promising response rates when infused after stem cell transplantation.Multiple myeloma (MM) is the second
most common hematological malignancy
characterized by the presence of a mono-
clonal immunoglobulin, clonal plasma
cell (PC) proliferation, bone lesions, hy-
percalcemia, anemia, and/or renal failure.
MM treatment has improved in the
last 15 years with the introduction of
immunomodulatory drugs (IMIDs) and
proteasome inhibitors and, more recently,
monoclonal antibodies (MoAbs) and
HDAC inhibitors, among others (Ocio
et al., 2014). Although such improvements
prolong patients’ survival, MM is still
incurable, and more effective treatments
are needed. The efficacy of immunothera-peutic strategies in solid and hematologic
tumors has stimulated their investigation
in MM.
Several lines of evidence support a role
for immunotherapy in MM. The first
comes from the well-established efficacy
of allogeneic stem cell transplantation
and donor-lymphocyte infusions. The
second is the activity of IMIDs alone or
in combination with other drugs. The third
is the possibility to delay the progression
of high-risk smoldering MM patients by
increasing tumor surveillance of their
‘‘not-so-impaired’’ immune system with
IMIDs (Mateos et al., 2013). The fourth
is that long-term survival of MM patientsis associated with active immune sur-
veillance (Pessoa de Magalha˜es et al.,
2013). Vaccination combining different
antigen formats and adjuvants has also
been investigated in MM (Rosenblatt
et al., 2013), but active vaccine strategies
are restricted by the insufficient numbers
of induced T cells, their poor homing to
tumor sites, and the immunosuppressive
tumor microenvironment. The strategy of
isolating tumor infiltrating lymphocytes
(TILs), expanding them in vitro, and then
transferring them back to the patient
has also been investigated (Noonan
et al., 2015). Notwithstanding, the low
frequency of anti-tumor T cells remains aptember 14, 2015 ª2015 Elsevier Inc. 281
